Overview
Urokinase plasminogen activator (uPA) is a serine protease involved in tissue remodeling, cell migration, and fibrinolysis. It converts plasminogen into plasmin, leading to the breakdown of fibrin and extracellular matrix components. Plasminogen activator inhibitor-1 is a serine protease inhibitor that regulates fibrinolysis by inhibiting uPA and tissue-type plasminogen activator. Together, uPA and PAI-1 play a crucial role in maintaining balance between clot breakdown and tissue stability.
Both uPA and PAI-1 are strongly associated with tumor invasion, angiogenesis, and metastasis. Elevated levels of these markers are linked with poor prognosis, especially in breast cancer, and are widely used as prognostic and predictive biomarkers
Symptoms
uPA and PAI-1 themselves do not cause direct symptoms. Clinical manifestations depend on the underlying condition in which these markers are elevated.
In cancer patients, high levels are associated with aggressive tumor behavior, rapid disease progression, and increased risk of metastasis. Symptoms may include unexplained weight loss, fatigue, pain, and organ-specific manifestations depending on tumor spread.
In PAI-1 deficiency, patients may present with easy bruising, nosebleeds, gingival bleeding, joint bleeding, excessive menstrual bleeding, or prolonged bleeding after surgery or trauma.
Causes
Increased uPA levels occur due to enhanced tumor cell activity, where malignant cells produce and secrete uPA to facilitate tissue invasion and metastasis. uPA binds to its receptor on cell surfaces and promotes the degradation of the surrounding matrix.
Elevated PAI-1 levels result from increased production by endothelial cells and tumor cells. Although PAI-1 inhibits fibrinolysis, paradoxically, high levels promote tumor progression by stabilizing tumor architecture and supporting angiogenesis.
Congenital PAI-1 deficiency is caused by mutations in the SERPINE1 gene, leading to reduced or functionally inactive PAI-1 protein and resulting in bleeding tendencies.
Risk Factors
Risk factors for abnormal uPA and PAI-1 levels include breast cancer, advanced malignancy, and tumors with high metastatic potential. Patients with lymph node-negative breast cancer are often evaluated using these markers to guide chemotherapy decisions.
Genetic mutations affecting SERPINE1 increase the risk of congenital PAI-1 deficiency. A family history of bleeding disorders raises suspicion.
Surgical procedures, trauma, and systemic inflammation may unmask bleeding symptoms in individuals with underlying PAI-1 deficiency.
Prevention
There is no direct prevention for altered uPA or PAI-1 levels, as they reflect underlying pathological processes. Early detection and monitoring in breast cancer help guide treatment decisions and reduce overtreatment.
Genetic counseling and family screening are important in confirmed cases of congenital PAI-1 deficiency. Awareness of bleeding risk allows preventive planning before surgery or invasive procedures.
Regular follow-up, appropriate oncologic treatment, and clinical correlation of laboratory results help reduce complications and improve patient outcomes.
